viewBiocept Inc

Biocept brings tremendous value to the healthcare system with its AI partnership

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall tells Proactive Investors the California-based molecular diagnostics company is making progress on its artificial intelligence collaboration with Prognos Inc.

Nall says Prognos uses data that Biocept generates with its liquid biopsy tests from different cancers to analyze trends to identify and develop targeted therapies based on the genomic of a patient's tumor. Nall says investors should look out for how Biocept and Prognos sell this data to Big Pharma and create an additional revenue stream.

Quick facts: Biocept Inc

Price: 1.025 USD

Market: NASDAQ
Market Cap: $134.38 m

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Biocept Inc named herein, including the promotion by the Company of Biocept Inc in any Content on the Site, the Company receives from said...



Biocept to provide coronavirus test kits, will cover out-of-network patients...

Biocept Inc (NASDAQ:BIOC) CEO Mike Nall and CFO Tim Kennedy tell Proactive the California-based firm has solved supply chain problems of obtaining 10,000 testing kits to provide coronavirus test to patients. Separately, Nall says the firm has agreed to a managed care provider agreement with...

on 06/29/2020

2 min read